These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oral hypoglycemic agents in type II diabetes mellitus. Lubbos H; Miller JL; Rose LI Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707 [TBL] [Abstract][Full Text] [Related]
4. Glycaemic control in type 2 diabetes. Campbell A Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416 [No Abstract] [Full Text] [Related]
5. The management of non-insulin-dependent diabetes mellitus in the elderly. Ruoff G J Fam Pract; 1993 Mar; 36(3):329-35. PubMed ID: 8454981 [TBL] [Abstract][Full Text] [Related]
6. Use oral hypoglycemics with caution...but keep caution in context. Davidson MB Geriatrics; 1988 Aug; 43(8):83-4. PubMed ID: 3042515 [No Abstract] [Full Text] [Related]
7. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976 [TBL] [Abstract][Full Text] [Related]
8. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Buse JB Diabetes Care; 1999 Apr; 22 Suppl 3():C65-70. PubMed ID: 10189565 [No Abstract] [Full Text] [Related]
9. Oral hypoglycemic agents in the treatment of type II diabetes. Tal A Am Fam Physician; 1993 Nov; 48(6):1089-95. PubMed ID: 8237731 [TBL] [Abstract][Full Text] [Related]
10. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM). Capriotti T Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992 [No Abstract] [Full Text] [Related]
11. Rational choice of oral antihyperglycaemic agents. Chowdhury S; Sengupta N J Indian Med Assoc; 2002 Mar; 100(3):174-5, 177. PubMed ID: 12408278 [TBL] [Abstract][Full Text] [Related]
12. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [TBL] [Abstract][Full Text] [Related]
13. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures]. Tattersall RB Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219 [No Abstract] [Full Text] [Related]
14. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
15. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Harrigan RA; Nathan MS; Beattie P Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816 [TBL] [Abstract][Full Text] [Related]
16. [40 years of using sulfonylurea derivatives for treatment of diabetes]. Sieradzki J Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529 [TBL] [Abstract][Full Text] [Related]
18. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus. Graham JP; Stam D Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306 [TBL] [Abstract][Full Text] [Related]
19. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Ross SA; Zinman B; Campos RV; Strack T; Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232 [TBL] [Abstract][Full Text] [Related]